The purpose of this study is to evaluate the efficacy and safety of A-prexa compared to Zyprexa in patients with schizophrenia, schizophreniform disorder and schizoaffective disorder.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
64
Change from baseline at 6 week in total PANSS score
Time frame: 6 week
Change from baseline at 1, 2, 4 and 6 week in total PANSS score.
Time frame: 6 week
Responder to be decreased of 30% or more in PANSS total score from baseline at 6 week
Time frame: 6 week
Change from baseline at 6 week in total CGI-S score
Time frame: 6 week
Responder rate in CGI-I score of 'very much improved', 'much improved' and 'minimally improved'
Time frame: 6 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.